RetroSense Therapeutics, a Ann Arbor, MI-based biopharmaceutical company developing life-enhancing gene therapies, secured $6m in Series A financing.
Backers included Nerveda, Blue Water Angels, SDL Ventures, Tech Coast Angels, and Michigan Economic Development Corporation.
The company intends to use the funds to enable completion of preclinical studies needed to support an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration for its lead compound, RST-001 for the treatment of Retinitis Pigmentosa, a cause of vision loss and blindness.
Led by Sean Ainsworth, CEO, RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). The company’s approach to using optogenetics in vision restoration is based on proprietary research conducted at Wayne State University and Massachusetts General Hospital.
RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions.